Tuberous sclerosis

Tuberous sclerosis
Synonyms	Tuberous sclerosis complex, Bourneville disease
Field	Medical genetics, Neurology, Dermatology
Symptoms	Seizures, intellectual disability, autism spectrum disorder, skin lesions, kidney problems
Complications	Status epilepticus, renal cell carcinoma, lymphangioleiomyomatosis
Onset	Birth
Duration	Lifelong
Causes	Genetic disorder due to mutations in TSC1 or TSC2
Diagnosis	Clinical criteria, genetic testing, MRI, CT scan
Treatment	Anticonvulsants, mTOR inhibitors, surgery
Medication	Vigabatrin, everolimus, sirolimus
Prognosis	Variable
Frequency	~1 in 6,000

Tuberous sclerosis. It is a rare, multisystem genetic disorder characterized by the growth of numerous noncancerous hamartomas in various organs. The condition arises from mutations in either the TSC1 gene or the TSC2 gene, leading to constitutive activation of the mammalian target of rapamycin (mTOR) pathway. Clinical manifestations are highly variable, affecting the brain, skin, kidneys, heart, and lungs, with neurological and dermatological features being most prominent.

Signs and symptoms

The clinical presentation is extraordinarily heterogeneous, with manifestations ranging from mild skin findings to severe neurological disability. Classic neurological features include epilepsy, often presenting as infantile spasms, and cognitive impairment, which can be associated with autism spectrum disorder and attention deficit hyperactivity disorder. Characteristic skin lesions include hypomelanotic macules (ash-leaf spots), facial angiofibromas (adenoma sebaceum), shagreen patches, and forehead plaques. Major internal organ involvement includes cardiac rhabdomyomas, which are often detected prenatally via fetal ultrasound, and renal angiomyolipomas, which can cause hemorrhage or renal failure. Pulmonary manifestations, such as lymphangioleiomyomatosis, primarily affect adult women and can lead to pneumothorax or respiratory failure.

Genetics

This is an autosomal dominant disorder with high penetrance but variable expressivity. Approximately two-thirds of cases are due to de novo germline mutations, with the remainder inherited from an affected parent. The disorder is caused by inactivating mutations in either the TSC1 gene on chromosome 9 or the TSC2 gene on chromosome 16. The TSC2 gene is adjacent to the PKD1 gene, and large deletions affecting both can result in a severe phenotype with early-onset polycystic kidney disease. Genetic testing, often involving sequence analysis and deletion/duplication analysis, confirms the diagnosis and enables genetic counseling for families.

Pathophysiology

The proteins encoded by TSC1 (hamartin) and TSC2 (tuberin) form a functional complex that acts as a critical negative regulator of the mTOR signaling pathway. Loss-of-function mutations in either gene lead to constitutive activation of mTOR complex 1, resulting in uncontrolled cell growth, cell proliferation, and protein synthesis. This aberrant signaling drives the development of hamartomas, which are disorganized but benign growths composed of cells native to the organ. In the brain, these manifest as cortical tubers and subependymal nodules, which are the pathological substrates for seizures and neurodevelopmental issues.

Diagnosis

Diagnosis is based on established clinical criteria, which categorize features as major or minor, or through the identification of a pathogenic mutation in TSC1 or TSC2. Key diagnostic tools include neuroimaging such as magnetic resonance imaging of the brain to identify cortical tubers and subependymal giant cell astrocytoma, and computed tomography or ultrasound of the abdomen to visualize renal angiomyolipomas. Dermatological examination under Wood's lamp can highlight hypomelanotic macules. Electroencephalogram is used to evaluate epilepsy, while echocardiogram assesses cardiac rhabdomyomas.

Management

Management is multidisciplinary, involving specialists in neurology, nephrology, dermatology, pulmonology, and genetics. The cornerstone of neurological treatment is control of seizures with anticonvulsants; vigabatrin is particularly effective for infantile spasms. The mTOR inhibitors everolimus and sirolimus are approved for treating specific manifestations, including subependymal giant cell astrocytoma, renal angiomyolipoma, and lymphangioleiomyomatosis. Dermatologic surgery or laser therapy may be used for disfiguring facial angiofibromas. Regular surveillance with MRI, renal ultrasound, and pulmonary function tests is critical for early detection of complications.

Prognosis

The prognosis varies widely and is largely dependent on the extent of neurological and renal involvement. Individuals with well-controlled epilepsy and normal intelligence can have a normal life expectancy. However, severe refractory epilepsy, infantile spasms, and the presence of numerous cortical tubers are associated with a poorer neurodevelopmental outcome. Major causes of morbidity and mortality include complications from renal angiomyolipomas, such as retroperitoneal hemorrhage, progression of lymphangioleiomyomatosis, and malignant transformation, though rare, to renal cell carcinoma. Lifelong, organ-specific monitoring is essential.

Category:Genetic disorders Category:Neurological disorders Category:Rare diseases